As of 2025-05-20, the Intrinsic Value of Nymox Pharmaceutical Corp (NYMX) is -1.48 USD. This NYMX valuation is based on the model Peter Lynch Fair Value. With the current market price of 0.20 USD, the upside of Nymox Pharmaceutical Corp is -839.95%.
Based on its market price of 0.20 USD and our intrinsic valuation, Nymox Pharmaceutical Corp (NYMX) is overvalued by 839.95%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -1.48 - -1.48 | -1.48 | -839.95% |
| P/E | (0.04) - (0.05) | (0.05) | -123.6% |
| DDM - Stable | (0.87) - (5.28) | (3.08) | -1639.0% |
| DDM - Multi | (0.80) - (3.85) | (1.33) | -766.1% |
| Market Cap (mil) | 18.10 |
| Beta | 0.02 |
| Outstanding shares (mil) | 90.51 |
| Enterprise Value (mil) | 18.78 |
| Market risk premium | 5.00% |
| Cost of Equity | 7.54% |
| Cost of Debt | 5.00% |
| WACC | 7.50% |